Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Condition(s) studied
Investigational drug(s) / intervention(s)
Nexium 20mg: Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Nexium 10mg: Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Study summary
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Eligibility
Primary outcome measure(s)
- Presence / absence of Erosive Esophagitis — Week 24 (end of 16-week maintenance phase)
Presence/absence of Erosive Esophagitis for all patients by assessment of Esophagogastroduodenoscopy at the end of the 16-week maintenance phase
Trial sites (41)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Mobile | Alabama | |
| Research Site | Sacramento | California | |
| Research Site | Miami | Florida | |
| Research Site | Miami | Florida | |
| Research Site | Orlando | Florida | |
| Research Site | Carmel | Indiana | |
| Research Site | Shreveport | Louisiana | |
| Research Site | The Bronx | New York | |
| Research Site | Akron | Ohio | |
| Research Site | Cleveland | Ohio | |
| Research Site | Milwaukee | Wisconsin | |
| Research Site | Córdoba | Argentina | |
| Research Site | Córdoba | Argentina | |
| Research Site | Paraná | Argentina | |
| Research Site | Rosario | Argentina | |
| Research Site | Clayton | Australia | |
| Research Site | Namur | Belgium | |
| Research Site | Athens | Greece | |
| Research Site | Thessaloniki | Greece | |
| Research Site | Thessaloniki | Greece | |
| Research Site | Messina | Italy | |
| Research Site | Naples | Italy | |
| Research Site | Naples | Italy | |
| Research Site | Roma | Italy | |
| Research Site | Roma | Italy | |
| Research Site | Vilnius | Lithuania | |
| Research Site | Coimbra | Portugal | |
| Research Site | Lisbon | Portugal | |
| Research Site | Lisbon | Portugal | |
| Research Site | Lisbon | Portugal | |
| Research Site | Porto | Portugal | |
| Research Site | Porto | Portugal | |
| Research Site | Viana do Castelo | Portugal | |
| Research Site | Badalona | Spain | |
| Research Site | Santiago de Compostela | Spain | |
| Research Site | Seville | Spain | |
| Research Site | Seville | Spain | |
| Research Site | Hanoi | Vietnam | |
| Research Site | Hanoi | Vietnam | |
| Research Site | Hà Nội | Vietnam |
+ 1 more sites — see the full list on the official registry below.
More AstraZeneca trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05267613 on ClinicalTrials.gov ↗ ← All trials in Italy